FDAnews
www.fdanews.com/articles/127190-gsk-halts-promacta-trial-due-to-thrombotic-events

GSK Halts Promacta Trial Due to Thrombotic Events

May 19, 2010
GlaxoSmithKline said it halted a trial of its low blood platelet treatment Promacta in patients with liver disease after six patients in the study (4 percent of the total group) experienced blood clots. The company also is working with the FDA to change the labeling for Promacta (eltrombopag) to include safety information specific to this situation. In a May 4 letter to healthcare professionals posted on the FDA’s MedWatch website, the company said Promacta is not approved in patients with chronic liver disease.
Washington Drug Letter